Galectin‐1 promotes an M2 macrophage response to polydioxanone scaffolds

Abebayehu, Daniel; Spence, Andrew J.; Boyan, Barbara D.; Schwartz, Zvi; Ryan, John; McClure, Michael J.

doi:10.1002/jbm.a.36113

Cited by 24 publications

(19 citation statements)

References 51 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inflammation induced by zymosan is reliant on the activation of peritoneal macrophages via TLR2; evidence exists in the literature that exogenous Gal-1 reduces pro-inflammatory cytokine production from murine macrophages (Fredman et al, 2012;Abebayehu et al, 2017) and skews toward an M2 (Barrionuevo et al, 2007) and pro-resolving phenotype (Fredman et al, 2012). Additionally, macrophages from Gal-1 KO mice have FIGURE 4 | hrGal-1 administration following the peak of inflammation shortened the resolution interval.…”

Section: Discussionmentioning

confidence: 99%

A Pro-resolving Role for Galectin-1 in Acute Inflammation

et al. 2020

View full text Add to dashboard Cite

Galectin-1 (Gal-1) exerts immune-regulatory and anti-inflammatory actions in animal models of acute and chronic inflammation. Its release into the extracellular milieu often correlates with the peak of inflammation suggesting that it may serve a pro-resolving function. Gal-1 is reported to inhibit neutrophil recruitment and induce surface exposure of phosphatidylserine (PS), an "eat me" signal on the surface of neutrophils, yet its role in resolution remains to be fully elucidated. We hypothesized that the anti-inflammatory and pro-resolving properties of Gal-1 are mediated through its ability to inhibit neutrophil recruitment and potentiate neutrophil clearance. To investigate this, a murine model of self-resolving inflammation was utilized to uncover the role of both the endogenous and exogenous protein using Gal-1 null mice and recombinant protein, respectively. We found that peritoneal macrophages express increased Gal-1 during the resolution phase and enhanced neutrophil recruitment occurs in the early phases of zymosan peritonitis in Gal-1 null mice compared to their wild-type (WT) counterparts. Administration of recombinant Gal-1 following the peak of inflammation led to reduced neutrophil numbers at 24 and 48 h, shortening the resolution interval from 39 to 14 h. Gal-1 treatment also enhanced neutrophil apoptosis, indicating a pro-resolving action. Together these results indicate an important role for Gal-1 in the timely resolution of acute inflammation.

show abstract

Section: Discussionmentioning

confidence: 99%

A Pro-resolving Role for Galectin-1 in Acute Inflammation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Abebayehu et al incorporated galectin-1, an immunosuppressive protein, into small and large fiber polydioxanone scaffolds. [118] This modification was sufficient to shift macrophage commitment to an M2-like phenotype on the small diameter fibers. Likewise, functionalization with chondroitin sulfate (CS), a glycosaminoglycan, decreased macrophage inflammation by impeding CD44 binding, preventing the LPS/CD44/NF-κB inflammatory cascade.…”

Section: Implantable Scaffoldsmentioning

confidence: 95%

“…Overall, fiber diameter had a more significant impact on the inflammatory response: smaller fibers induced M1‐like phenotype, while larger fibers induced an M2‐like phenotype. Abebayehu et al incorporated galectin‐1, an immunosuppressive protein, into small and large fiber polydioxanone scaffolds . This modification was sufficient to shift macrophage commitment to an M2‐like phenotype on the small diameter fibers.…”

Section: Localized Tam Modulation By Biomaterials: Lessons From Woundmentioning

confidence: 99%

Progress on Modulating Tumor‐Associated Macrophages with Biomaterials

2019

View full text Add to dashboard Cite

Tumor‐associated macrophages (TAMs) are a complex and heterogeneous population of cells within the tumor microenvironment. In many tumor types, TAMs contribute toward tumor malignancy and are therefore a therapeutic target of interest. Here, three major strategies for regulating TAMs are highlighted, emphasizing the role of biomaterials in these approaches. First, systemic methods for targeting tumor‐associated macrophage are summarized and limitations to both passive and active targeting approaches considered. Second, lessons learned from the significant literature on wound healing and macrophage response to implanted biomaterials are discussed with the vision of applying these principles to localized, biomaterial‐based modulation of tumor‐associated macrophage. Finally, the developing field of engineered macrophages, including genetic engineering and integration with biomaterials or drug delivery systems, is examined. Analysis of major challenges in the field along with exciting opportunities for the future of macrophage‐based therapies in oncology are included.

show abstract

“…Moreover, Galectin-1 showed activity on macrophage homeostasis. It induces macrophage M2 phenotype, suggesting its potential role in the control of macrophage function during the resolution of inflammation (Abebayehu et al, 2017). It also participates to modulation of inflammation through inducing apoptosis by binding to CD45+ cells (Sasaguri et al, 2017).…”

Section: Variables Statisticsmentioning

confidence: 99%

Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis

Bennett

Bargagli

Bianchi

et al. 2020

Respiratory Physiology & Neurobiology

View full text Add to dashboard Cite

Galectin-1 is a carbohydrate-binding protein involved in apoptosis, cell-proliferation and differentiation, implicated in T-cell homeostasis and survival. The aim of the present study was to determine concentrations of galectin-1 in BAL fluid from patients with IPF and other interstitial lung diseases in order to validate proteomic previous findings. Methods: 36 IPF patients (16 females, mean age of 64.8 ± 8.9 years), 24 sarcoidosis patients (15 females, mean age of 56.3 ± 13.4), 7 interstitial lung diseases associated to systemic sclerosis (ILD-SSc) patients (5 females, mean age of 55.5 ± 16.4) and six healthy controls (4 females, mean age 47.8 ± 15.2) were included. Galectin-1 concentrations were determined in BAL samples by an ELISA assay. Results: Galectin-1 concentrations were significantly higher in BAL of IPF patients than in sarcoidosis and ILD-SSc patients and healthy controls. In IPF patients, galectin-1 levels showed significant inverse correlations with DL CO %, K CO % and BAL lymphocyte percentages and a positive correlation with BAL macrophage percentages. Former IPF smokers had higher concentrations of this protein compared with non-smoker IPF patients. Conclusion: Galectin-1 was confirmed a protein of interest in idiopathic pulmonary fibrosis. Its BAL concentrations were higher in IPF patients than in controls and correlated with disease severity. Galectin-1 was suggested to have a role in the pathogenesis of IPF, principally through the ERK/MAPK pathway and the inhibition of galectin-1 is a potential therapeutic target worthy of research.

show abstract

Galectin‐1 promotes an M2 macrophage response to polydioxanone scaffolds

Cited by 24 publications

References 51 publications

A Pro-resolving Role for Galectin-1 in Acute Inflammation

A Pro-resolving Role for Galectin-1 in Acute Inflammation

Progress on Modulating Tumor‐Associated Macrophages with Biomaterials

Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis

Contact Info

Product

Resources

About